{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:53:13Z","timestamp":1794484393128,"version":"4.9.1"},"reference-count":313,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In solid tumors, the tumor microenvironment (TME) is a complex mix of tumor, immune, stromal cells, fibroblasts, and the extracellular matrix. Cytotoxic T lymphocytes (CTLs) constitute a fraction of immune cells that may infiltrate into the TME. The primary function of these T-cells is to detect and eliminate tumor cells. However, due to the immunosuppressive factors present in the TME primarily mediated by Myeloid-Derived Suppressor Cells (MDSCs), Tumor associated macrophages (TAMs), Cancer Associated Fibroblasts (CAFs) as well as the tumor cells themselves, T-cells fail to differentiate into effector cells or become dysfunctional and are unable to eliminate the tumor. In addition, chronic antigen stimulation within the TME also leads to a phenomenon, first identified in chronic lymphocytic choriomeningitis virus (LCMV) infection in mice, where the T-cells become exhausted and lose their effector functions. Exhausted T-cells (Tex) are characterized by the presence of remarkably conserved inhibitory receptors, transcription and signaling factors and the downregulation of key effector molecules. Tex cells have been identified in various malignancies, including melanoma, colorectal and hepatocellular cancers. Recent studies have indicated novel strategies to reverse T-cell exhaustion. These include checkpoint inhibitor blockade targeting programmed cell death protein 1 (PD-1), T-cell immunoglobulin and mucin-domain containing-3 (Tim-3), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), or combinations of different immune checkpoint therapies (ICTs) or combination of ICTs with cytokine co-stimulation. In this review, we discuss aspects of T-cell dysfunction within the TME with a focus on T-cell exhaustion. We believe that gaining insight into the mechanisms of T-cell exhaustion within the TME of human solid tumors will pave the way for developing therapeutic strategies to target and potentially re-invigorate exhausted T-cells in cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1548234","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:30:03Z","timestamp":1743467403000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":94,"title":["Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies"],"prefix":"10.3389","volume":"16","author":[{"given":"Reshmi","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Kuriakose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Ram","family":"Krishn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Raben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B2","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.01.010","article-title":"Gut microbiota in cancer immune response and immunotherapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Trends Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.03.039","article-title":"Common-lymphoid-progenitor-independent pathways of innate and T lymphocyte development","volume":"15","author":"Ghaedi","year":"2016","journal-title":"Cell Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see (and don\u2019t see)","volume":"14","author":"Klein","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006957","article-title":"T-cell tolerance: central and peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2003.01738.x","article-title":"The MHC class I antigen presentation pathway: strategies for viral immune evasion","volume":"110","author":"Hewitt","year":"2003","journal-title":"Immunology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v18.i4.40","article-title":"Positive and negative thymocyte selection","volume":"18","author":"Saito","year":"1998","journal-title":"Crit Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2018.08.001","article-title":"Cancer immunosurveillance by T cells","volume":"342","author":"Rao","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010138","article-title":"Post-translational modifications in tumor-associated antigens as a platform for novel immuno-oncology therapies","volume":"15","author":"Srivastava","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/sonc.2002.33076","article-title":"Immunologic mechanisms of antitumor activity","volume":"29","author":"Foss","year":"2002","journal-title":"Semin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: A milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T-cell exhaustion: characteristics, causes and conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/imm.v162.2","article-title":"Targeting metabolism to reverse T-cell exhaustion in chronic viral infections","volume":"162","author":"Sears","year":"2021","journal-title":"Immunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0092-8674(01)00185-4","article-title":"T cell receptor-MHC interactions up close","volume":"104","author":"Hennecke","year":"2001","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0605","article-title":"Hallmarks of T-cell exit from quiescence","volume":"6","author":"Chapman","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","article-title":"Cytokine regulation and function in T cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nature25144","article-title":"Effector CD8 T cells dedifferentiate into long-lived memory cells","volume":"552","author":"Youngblood","year":"2017","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02692","article-title":"Defining memory CD8 T cell","volume":"9","author":"Martin","year":"2018","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"108748","DOI":"10.1016\/j.celrep.2021.108748","article-title":"Dynamic adoption of anergy by antigen-exhausted CD4(+) T cells","volume":"34","author":"Trefzer","year":"2021","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119744109","article-title":"Tumor suppressor TSC1 is critical for T-cell anergy","volume":"109","author":"Xie","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00767-5","article-title":"Transcriptional mechanisms underlying lymphocyte tolerance","volume":"109","author":"Macian","year":"2002","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00454-2","article-title":"Rethinking peripheral T cell tolerance: checkpoints across a T cell\u2019s journey","volume":"21","author":"ElTanbouly","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ni1193","article-title":"Egr-2 and Egr-3 are negative regulators of T cell activation","volume":"6","author":"Safford","year":"2005","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141110","article-title":"T cell anergy","volume":"21","author":"Schwartz","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00927-z","article-title":"Hallmarks of T cell aging","volume":"22","author":"Mittelbrunn","year":"2021","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2981","article-title":"The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells","volume":"15","author":"Lanna","year":"2014","journal-title":"Nat Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3665","article-title":"A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging","volume":"18","author":"Lanna","year":"2017","journal-title":"Nat Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0643-3","article-title":"Sestrins induce natural killer function in senescent-like CD8(+) T cells","volume":"21","author":"Pereira","year":"2020","journal-title":"Nat Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02569","article-title":"T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses","volume":"9","author":"Saeidi","year":"2018","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0277-x","article-title":"The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity","volume":"30","author":"Schnell","year":"2020","journal-title":"Cell Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci Adv"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba7918","article-title":"TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells","volume":"5","author":"Sekine","year":"2020","journal-title":"Sci Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151632","article-title":"Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities","volume":"14","author":"Brunell","year":"2023","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.11.5535-5545.2004","article-title":"Memory CD8 T-cell differentiation during viral infection","volume":"78","author":"Wherry","year":"2004","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","article-title":"Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1(+) stem-like CD8(+) T cells during chronic infection","volume":"51","author":"Hudson","year":"2019","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.977394","article-title":"T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133679","article-title":"Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy","volume":"130","author":"Liu","year":"2020","journal-title":"J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1937123","article-title":"Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations","volume":"25","author":"Tabana","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2100588118","article-title":"Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer","volume":"118","author":"Wei","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B58","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.832206","article-title":"CD8(+) T-cell exhaustion phenotype in chronic hepatitis C virus infection is associated with epitope sequence variation","volume":"13","author":"Osuch","year":"2022","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11010101","article-title":"Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines","volume":"11","author":"Dhawan","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202617","article-title":"Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection","volume":"218","author":"Le Bert","year":"2021","journal-title":"J Exp Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04160320","article-title":"Clinical features of maintenance hemodialysis patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"15","author":"Wu","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12964-022-00856-w","article-title":"A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)","volume":"20","author":"Mohammed","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/imm.v162.1","article-title":"T-cell responses and therapies against SARS-CoV-2 infection","volume":"162","author":"Toor","year":"2021","journal-title":"Immunology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03862-z","article-title":"Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer","volume":"597","author":"Eberhardt","year":"2021","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.6853","article-title":"Hepatoma cells up-regulate expression of programmed cell death-1 on T cells","volume":"14","author":"Chen","year":"2008","journal-title":"World J Gastroenterol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.adh8697","article-title":"Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity","volume":"384","author":"Houlahan","year":"2024","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201966","article-title":"TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion","volume":"219","author":"Shakiba","year":"2022","journal-title":"J Exp Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101587","article-title":"Gut microbiota and immune system interactions","volume":"8","author":"Yoo","year":"2020","journal-title":"Microorganisms"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20160510","article-title":"Introduction to the human gut microbiota","volume":"474","author":"Thursby","year":"2017","journal-title":"Biochem J"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdz224","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"30","author":"Chaput","year":"2019","journal-title":"Ann Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","first-page":"101514","DOI":"10.1016\/j.xcrm.2024.101514","article-title":"Microbiome and cancer immunotherapies","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B80","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mi.2014.44","article-title":"Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway","volume":"8","author":"Park","year":"2015","journal-title":"Mucosal Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41419-023-05560-2","article-title":"Potential links between the microbiota and T cell immunity determine the tumor cell fate","volume":"14","author":"Mohseni","year":"2023","journal-title":"Cell Death Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"107471","DOI":"10.1016\/j.celrep.2020.03.035","article-title":"Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis","volume":"31","author":"Yu","year":"2020","journal-title":"Cell Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1030745","article-title":"Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00626-7","article-title":"Mitochondrial and metabolic dysfunction in ageing and age-related diseases","volume":"18","author":"Amorim","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.v8.11","article-title":"The clock is ticking: the impact of ageing on T cell metabolism","volume":"8","author":"Quinn","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75051","article-title":"p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8(+) T cells","volume":"124","author":"Henson","year":"2014","journal-title":"J Clin Invest"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aag0192","article-title":"Epigenomics of human CD8 T cell differentiation and aging","volume":"2","author":"Moskowitz","year":"2017","journal-title":"Sci Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1804149115","article-title":"Defective respiration and one-carbon metabolism contribute to impaired naive T cell activation in aged mice","volume":"115","author":"Ron-Harel","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1629258","article-title":"High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients","volume":"8","author":"Cao","year":"2019","journal-title":"Oncoimmunology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.05.002","article-title":"Immunometabolism: A \u2018Hot\u2019 Switch for \u2018Cold\u2019 Pediatric solid tumors","volume":"7","author":"Xiao","year":"2021","journal-title":"Trends Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69589","article-title":"Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function","volume":"123","author":"Sukumar","year":"2013","journal-title":"J Clin Invest"},{"key":"B93","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic regulation of T cell longevity and function in tumor immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy050","article-title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumours","volume":"29","author":"Aspeslagh","year":"2018","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj9123","article-title":"Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells","volume":"7","author":"Ford","year":"2022","journal-title":"Sci Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02430-9","article-title":"Histone deacetylase inhibition promotes intratumoral CD8(+) T-cell responses, sensitizing murine breast tumors to anti-PD1","volume":"68","author":"McCaw","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0134","article-title":"Modulation of antitumor immunity with histone deacetylase inhibitors","volume":"9","author":"McCaw","year":"2017","journal-title":"Immunotherapy"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v10.2","article-title":"Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer","volume":"10","author":"McCaw","year":"2021","journal-title":"Cancer Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.04.004","article-title":"Mechanisms of T cell exhaustion guiding next-generation immunotherapy","volume":"8","author":"Zebley","year":"2022","journal-title":"Trends Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1038\/s41467-021-27179-7","article-title":"LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah6499","article-title":"The epigenetic control of stemness in CD8(+) T cell fate commitment","volume":"359","author":"Pace","year":"2018","journal-title":"Science"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3213","article-title":"Tet2 inactivation enhances the antitumor activity of tumor-infiltrating lymphocytes","volume":"81","author":"Lee","year":"2021","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.146","article-title":"Epigenetic control of CD8(+) T cell differentiation","volume":"18","author":"Henning","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat Methods"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0206-z","article-title":"Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion","volume":"37","author":"Satpathy","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0135","article-title":"T cell stemness and dysfunction in tumors are triggered by a common mechanism","volume":"363","author":"Vodnala","year":"2019","journal-title":"Science"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41420-021-00556-3","article-title":"M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p\/YOD1\/YAP\/beta-catenin pathway","volume":"7","author":"Pu","year":"2021","journal-title":"Cell Death Discovery"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785222","article-title":"Neutrophil extracellular traps promote T cell exhaustion in the tumor microenvironment","volume":"12","author":"Kaltenmeier","year":"2021","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","article-title":"The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer","volume":"56","author":"Taifour","year":"2023","journal-title":"Immunity"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.873834","article-title":"Impact of drp1-mediated mitochondrial dynamics on T cell immune modulation","volume":"13","author":"Song","year":"2022","journal-title":"Front Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00868-7","article-title":"BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8(+) T cells","volume":"22","author":"Yao","year":"2021","journal-title":"Nat Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05105-1","article-title":"MYB orchestrates T cell exhaustion and response to checkpoint inhibition","volume":"609","author":"Tsui","year":"2022","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/s41467-021-21804-1","article-title":"Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma","volume":"12","author":"Hung","year":"2021","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","article-title":"Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1alpha-mediated glycolytic reprogramming","volume":"14","author":"Wu","year":"2023","journal-title":"Nat Commun"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1060112","article-title":"TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment","volume":"13","author":"Jantz-Naeem","year":"2023","journal-title":"Front Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1103823","article-title":"Crosstalk between fibroblasts and T cells in immune networks","volume":"13","author":"Lee","year":"2022","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001203","article-title":"Cancer-associated fibroblasts and T cells: from mechanisms to outcomes","volume":"206","author":"Baker","year":"2021","journal-title":"J Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1010428317718403","DOI":"10.1177\/1010428317718403","article-title":"The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"39","author":"Park","year":"2017","journal-title":"Tumour Biol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Ozdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"107701","DOI":"10.1016\/j.celrep.2020.107701","article-title":"Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer","volume":"31","author":"Becker","year":"2020","journal-title":"Cell Rep"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.48101\/ujms.v129.10710","article-title":"Interactions between cancer-associated fibroblasts and T-cells: functional crosstalk with targeting and biomarker potential","volume":"129","author":"Milosevic","year":"2024","journal-title":"Ups J Med Sci"},{"key":"B127","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1038\/s41467-024-53908-9","article-title":"Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer Malignancy","volume":"15","author":"Forsthuber","year":"2024","journal-title":"Nat Commun"},{"key":"B128","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12920-024-01863-1","article-title":"Analysis of cancer-associated fibroblasts related genes identifies COL11A1 associated with lung adenocarcinoma prognosis","volume":"17","author":"Zheng","year":"2024","journal-title":"BMC Med Genomics"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1004","article-title":"TAK1 promotes an immunosuppressive tumor microenvironment through cancer-associated fibroblast phenotypic conversion in pancreatic ductal adenocarcinoma","volume":"30","author":"Sheng","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-0940","article-title":"Inhibition of JNK signaling overcomes cancer-associated fibroblast-mediated immunosuppression and enhances the efficacy of immunotherapy in bladder cancer","volume":"84","author":"Cui","year":"2024","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"216985","DOI":"10.1016\/j.canlet.2024.216985","article-title":"Colorectal cancer-associated fibroblasts inhibit effector T cells via NECTIN2 signaling","volume":"595","author":"Agorku","year":"2024","journal-title":"Cancer Lett"},{"key":"B132","doi-asserted-by":"publisher","first-page":"113947","DOI":"10.1016\/j.yexcr.2024.113947","article-title":"Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming","volume":"435","author":"Wang","year":"2024","journal-title":"Exp Cell Res"},{"key":"B133","doi-asserted-by":"publisher","first-page":"112475","DOI":"10.1016\/j.celrep.2023.112475","article-title":"Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment","volume":"42","author":"Egan","year":"2023","journal-title":"Cell Rep"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0725-2","article-title":"Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen","volume":"21","author":"Vardhana","year":"2020","journal-title":"Nat Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B137","doi-asserted-by":"publisher","first-page":"7022337","DOI":"10.1155\/2023\/7022337","article-title":"The formation of NETs and their mechanism of promoting tumor metastasis","volume":"2023","author":"Li","year":"2023","journal-title":"J Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","article-title":"Plasmacytoid dendritic cells: development, regulation, and function","volume":"50","author":"Reizis","year":"2019","journal-title":"Immunity"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158044","article-title":"Review of dendritic cells, their role in clinical immunology, and distribution in various animal species","volume":"22","author":"Zanna","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2000.00121.x","article-title":"CD28, CTLA-4 and their ligands: who does what and to whom","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"104119","DOI":"10.1016\/j.cellimm.2020.104119","article-title":"The roles of tumor-associated macrophages in tumor angiogenesis and metastasis","volume":"353","author":"Fu","year":"2020","journal-title":"Cell Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295684","article-title":"Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs","volume":"14","author":"Shao","year":"2023","journal-title":"Front Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062998","article-title":"Involvement of IL-4, IL-13 and their receptors in pancreatic cancer","volume":"22","author":"Shi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B146","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.1038\/s41467-024-51978-3","article-title":"IL-4 drives exhaustion of CD8(+) CART cells","volume":"15","author":"Stewart","year":"2024","journal-title":"Nat Commun"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.21330","article-title":"Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N-glycosylation","volume":"6","author":"Araujo","year":"2017","journal-title":"Elife"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.20900\/immunometab20200020","article-title":"T cell metabolism in cancer immunotherapy","volume":"2","author":"Aksoylar","year":"2020","journal-title":"Immunometabolism"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00099","article-title":"Environmental and metabolic sensors that control T cell biology","volume":"6","author":"Ramsay","year":"2015","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","article-title":"The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function","volume":"20","author":"Macintyre","year":"2014","journal-title":"Cell Metab"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"B152","doi-asserted-by":"publisher","first-page":"103409","DOI":"10.1016\/j.ebiom.2021.103409","article-title":"Senescent T cells: a potential biomarker and target for cancer therapy","volume":"68","author":"Zhang","year":"2021","journal-title":"EBioMedicine"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.09.021","article-title":"The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation","volume":"35","author":"Wang","year":"2011","journal-title":"Immunity"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.4476","article-title":"Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways","volume":"180","author":"Jacobs","year":"2008","journal-title":"J Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3438","article-title":"Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation","volume":"17","author":"Pollizzi","year":"2016","journal-title":"Nat Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/nri1457","article-title":"IDO expression by dendritic cells: tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1347181","article-title":"Advances in reprogramming of energy metabolism in tumor T cells","volume":"15","author":"Xuekai","year":"2024","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu077","article-title":"Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation","volume":"26","author":"Eleftheriadis","year":"2014","journal-title":"Int Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1111\/imm.v167.4","article-title":"Metabolic plasticity and regulation of T cell exhaustion","volume":"167","author":"Li","year":"2022","journal-title":"Immunology"},{"key":"B160","year":""},{"key":"B161","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1165\/rcmb.2016-0037OC","article-title":"Programmed death-1 inhibition of phosphatidylinositol 3-kinase\/AKT\/mechanistic target of rapamycin signaling impairs sarcoidosis CD4(+) T cell proliferation","volume":"56","author":"Celada","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40169-016-0110-9","article-title":"Clinical significance of T cell metabolic reprogramming in cancer","volume":"5","author":"Herbel","year":"2016","journal-title":"Clin Transl Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-022-01017-3","article-title":"Lipid metabolism in T cell signaling and function","volume":"18","author":"Lim","year":"2022","journal-title":"Nat Chem Biol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-021-02123-w","article-title":"Immunosuppressive network promotes immunosenescence associated with aging and chronic inflammatory conditions","volume":"99","author":"Salminen","year":"2021","journal-title":"J Mol Med (Berl)"},{"key":"B166","year":""},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241165","article-title":"The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis","volume":"341","author":"Smith","year":"2013","journal-title":"Science"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.v10.1","article-title":"Analysis of single-cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma","volume":"10","author":"Yang","year":"2020","journal-title":"Clin Transl Med"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1542","article-title":"Tumor fibroblast-derived FGF2 regulates expression of SPRY1 in esophageal tumor-infiltrating T cells and plays a role in T-cell exhaustion","volume":"80","author":"Chen","year":"2020","journal-title":"Cancer Res"},{"key":"B172","doi-asserted-by":"publisher","first-page":"abe6474","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.767070","article-title":"Single-cell transcriptome analysis reveals RGS1 as a new marker and promoting factor for T-cell exhaustion in multiple cancers","volume":"12","author":"Bai","year":"2021","journal-title":"Front Immunol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"101568","DOI":"10.1016\/j.tranon.2022.101568","article-title":"Single-cell RNA sequencing analysis revealed cellular and molecular immune profiles in lung squamous cell carcinoma","volume":"27","author":"Hao","year":"2023","journal-title":"Transl Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215183","article-title":"Heterogeneity and differentiation trajectories of infiltrating CD8+ T cells in lung adenocarcinoma","volume":"14","author":"Song","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1003419","article-title":"Single-cell transcriptome analysis reveals heterogeneity and convergence of the tumor microenvironment in colorectal cancer","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204951","article-title":"Single-cell landscape highlights heterogenous microenvironment, novel immune reaction patterns, potential biomarkers and unique therapeutic strategies of cervical squamous carcinoma, human papillomavirus-associated (HPVA) and non-HPVA adenocarcinoma","volume":"10","author":"Qiu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24524","article-title":"Single-cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile","volume":"83","author":"Adorno Febles","year":"2023","journal-title":"Prostate"},{"key":"B179","doi-asserted-by":"publisher","first-page":"591","DOI":"10.32604\/or.2023.029282","article-title":"System analysis based on the T cell exhaustion\u2212related genes identifies CD38 as a novel therapy target for ovarian cancer","volume":"31","author":"Shi","year":"2023","journal-title":"Oncol Res"},{"key":"B180","doi-asserted-by":"publisher","first-page":"12801","DOI":"10.1038\/s41598-023-39208-0","article-title":"Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis","volume":"13","author":"Guo","year":"2023","journal-title":"Sci Rep"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.v13.9","article-title":"Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer","volume":"13","author":"Gao","year":"2023","journal-title":"Clin Transl Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14060667","article-title":"Identification and validation of T-cell exhaustion signature for predicting prognosis and immune response in pancreatic cancer by integrated analysis of single-cell and bulk RNA sequencing data","volume":"14","author":"Zhu","year":"2024","journal-title":"Diagn (Basel)"},{"key":"B183","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1038\/s41598-024-58419-7","article-title":"Novel T cell exhaustion gene signature to predict prognosis and immunotherapy response in thyroid carcinoma from integrated RNA-sequencing analysis","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90077-9","article-title":"CD27: marker and mediator of T-cell activation","volume":"15","author":"Hintzen","year":"1994","journal-title":"Immunol Today"},{"key":"B185","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700606","article-title":"CD27-mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy","volume":"199","author":"Wasiuk","year":"2017","journal-title":"J Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401644","article-title":"OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence","volume":"194","author":"Buchan","year":"2015","journal-title":"J Immunol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41467-022-35238-w","article-title":"A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer","volume":"14","author":"Tietscher","year":"2023","journal-title":"Nat Commun"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.v9.4","article-title":"Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers","volume":"9","author":"Navani","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"B191","doi-asserted-by":"publisher","first-page":"101640","DOI":"10.1016\/j.xcrm.2024.101640","article-title":"Pan-cancer mapping of single CD8(+) T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity","volume":"5","author":"Tooley","year":"2024","journal-title":"Cell Rep Med"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v147.9","article-title":"Genetically driven CD39 expression shapes human tumor-infiltrating CD8(+) T-cell functions","volume":"147","author":"Gallerano","year":"2020","journal-title":"Int J Cancer"},{"key":"B193","doi-asserted-by":"publisher","first-page":"2346359","DOI":"10.1080\/2162402X.2024.2346359","article-title":"Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction","volume":"13","author":"Witt","year":"2024","journal-title":"Oncoimmunology"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192080","article-title":"Layilin augments integrin activation to promote antitumor immunity","volume":"217","author":"Mahuron","year":"2020","journal-title":"J Exp Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00006","article-title":"LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers","volume":"10","author":"Pan","year":"2019","journal-title":"Front Immunol"},{"key":"B196","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12672-024-00913-5","article-title":"The prognostic value of LAYN in HPV-related head and neck squamous cell carcinoma and its influence on immune cell infiltration","volume":"15","author":"Chen","year":"2024","journal-title":"Discovery Oncol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-022-00718-0","article-title":"Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8(+)T cells","volume":"45","author":"Yang","year":"2022","journal-title":"Cell Oncol (Dordr)"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S464806","article-title":"LAYN serves as a prognostic biomarker and downregulates tumor-infiltrating CD8(+) T cell function in hepatocellular carcinoma","volume":"11","author":"Xiao","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0539","article-title":"NKG7 is a T-cell-intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy","volume":"10","author":"Wen","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.931630","article-title":"NKG7 enhances CD8+ T cell synapse efficiency to limit inflammation","volume":"13","author":"Lelliott","year":"2022","journal-title":"Front Immunol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"19142","DOI":"10.1038\/s41598-024-70184-1","article-title":"Identification of the novel exhausted T cell CD8 + markers in breast cancer","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1838141","DOI":"10.1080\/2162402X.2020.1838141","article-title":"Tumor-infiltrating TNFRSF9(+) CD8(+) T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response","volume":"9","author":"Li","year":"2020","journal-title":"Oncoimmunology"},{"key":"B203","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12672-024-00951-z","article-title":"Pan-cancer analysis for the prognostic and immunological role of CD47: interact with TNFRSF9 inducing CD8 + T cell exhaustion","volume":"15","author":"Liang","year":"2024","journal-title":"Discovery Oncol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"171520","DOI":"10.1155\/2015\/171520","article-title":"Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells","volume":"2015","author":"Ronchetti","year":"2015","journal-title":"J Immunol Res"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1137025","article-title":"T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing","volume":"14","author":"Chi","year":"2023","journal-title":"Front Immunol"},{"key":"B206","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jcmgh.2022.09.007","article-title":"GITR ligation improves anti-PD1-mediated restoration of human MMR-proficient colorectal carcinoma tumor-derived T cells","volume":"15","author":"Rakke","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.molcel.2022.12.029","article-title":"Integrated single-cell profiling dissects cell-state-specific enhancer landscapes of human tumor-infiltrating CD8(+) T cells","volume":"83","author":"Riegel","year":"2023","journal-title":"Mol Cell"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198551","article-title":"Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade","volume":"14","author":"Tian","year":"2023","journal-title":"Front Immunol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.11.035","article-title":"TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer","volume":"499","author":"Han","year":"2021","journal-title":"Cancer Lett"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.990419","article-title":"TOX regulates T lymphocytes differentiation and its function in tumor","volume":"14","author":"Niu","year":"2023","journal-title":"Front Immunol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2019.8.issue-6","article-title":"Prognostic role of cyclin D2\/D3 in multiple human Malignant neoplasms: A systematic review and meta-analysis","volume":"8","author":"Ding","year":"2019","journal-title":"Cancer Med"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-1863","article-title":"CCND2 is a prognostic biomarker and correlates with immune infiltration in lung adenocarcinoma","volume":"13","author":"Jia","year":"2024","journal-title":"Transl Cancer Res"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0045-3","article-title":"Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing","volume":"24","author":"Guo","year":"2018","journal-title":"Nat Med"},{"key":"B216","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s42003-023-04521-x","article-title":"Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8(+) T cells in hepatocellular carcinoma","volume":"6","author":"Pan","year":"2023","journal-title":"Commun Biol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06733-x","article-title":"Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer","volume":"624","author":"Zhou","year":"2023","journal-title":"Nature"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1002\/eji.2015.45.issue-10","article-title":"Hobit and human effector T-cell differentiation: The beginning of a long journey","volume":"45","author":"Braun","year":"2015","journal-title":"Eur J Immunol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"110520","DOI":"10.1016\/j.isci.2024.110520","article-title":"TGF-beta neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice","volume":"27","author":"Fay","year":"2024","journal-title":"iScience"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.v12.10","article-title":"Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma","volume":"12","author":"Li","year":"2022","journal-title":"Clin Transl Med"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00535","article-title":"The transcription factor ZNF683\/HOBIT regulates human NK-cell development","volume":"8","author":"Post","year":"2017","journal-title":"Front Immunol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12967-023-04112-8","article-title":"Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma","volume":"21","author":"Chen","year":"2023","journal-title":"J Transl Med"},{"key":"B223","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1038\/s41467-024-46912-6","article-title":"Single cell deciphering of progression trajectories of the tumor ecosystem in head and neck cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B224","doi-asserted-by":"publisher","first-page":"1915560","DOI":"10.1080\/2162402X.2021.1915560","article-title":"Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients","volume":"10","author":"Jin","year":"2021","journal-title":"Oncoimmunology"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03496-2","article-title":"Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment","volume":"72","author":"Maldonado","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3311","article-title":"T cell-induced CSF1 promotes melanoma resistance to PD1 blockade","volume":"10","author":"Neubert","year":"2018","journal-title":"Sci Transl Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207619","article-title":"CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v135.6","article-title":"Crucial involvement of the CCL3-CCR5 axis-mediated fibroblast accumulation in colitis-associated carcinogenesis in mice","volume":"135","author":"Sasaki","year":"2014","journal-title":"Int J Cancer"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg3868","article-title":"Cellular and molecular waypoints along the path of T cell exhaustion","volume":"8","author":"Lan","year":"2023","journal-title":"Sci Immunol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"107847","DOI":"10.1016\/j.celrep.2020.107847","article-title":"Extracellular granzyme A promotes colorectal cancer development by enhancing gut inflammation","volume":"32","author":"Santiago","year":"2020","journal-title":"Cell Rep"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S400808","article-title":"Identification of GZMA as a potential therapeutic target involved in immune infiltration in breast cancer by integrated bioinformatical analysis","volume":"15","author":"Huo","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.04.001","article-title":"The untold story of granzymes in oncoimmunology: novel opportunities with old acquaintances","volume":"3","author":"Arias","year":"2017","journal-title":"Trends Cancer"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010089","article-title":"The dark side of IFN-gamma: its role in promoting cancer immunoevasion","volume":"19","author":"Mojic","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1038\/nri911","article-title":"Functional significance of the perforin\/granzyme cell death pathway","volume":"2","author":"Trapani","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"101042","DOI":"10.1016\/j.tranon.2021.101042","article-title":"PRF1 is a prognostic marker and correlated with immune infiltration in head and neck squamous cell carcinoma","volume":"14","author":"Fan","year":"2021","journal-title":"Transl Oncol"},{"key":"B236","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-gamma in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"biomark Res"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1371743","article-title":"Granzymes in health and diseases: the good, the bad and the ugly","volume":"15","author":"Cigalotto","year":"2024","journal-title":"Front Immunol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab: first global approval","volume":"71","author":"Cameron","year":"2011","journal-title":"Drugs"},{"key":"B239","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40265-022-01827-8","article-title":"Tremelimumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01539-5","article-title":"Dostarlimab: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B242","article-title":"Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B243","first-page":"96","article-title":"Keytruda (Pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01884-7","article-title":"Retifanlimab: first approval","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: first approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0618-8","article-title":"Atezolizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0749-6","article-title":"Avelumab: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab plus relatlimab: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B250","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683419","article-title":"FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0147","article-title":"Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 checkMate 714 randomized clinical trial","volume":"9","author":"Harrington","year":"2023","journal-title":"JAMA Oncol"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andre","year":"2022","journal-title":"Ann Oncol"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v126.18","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br J Cancer"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx008","article-title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","volume":"28","author":"Hui","year":"2017","journal-title":"Ann Oncol"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B263","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008872","article-title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","volume":"12","author":"Schenker","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50%: randomized, double-blind phase III KEYNOTE-598 study","volume":"39","author":"Boyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"B269","doi-asserted-by":"publisher","first-page":"2261248","DOI":"10.1080\/2162402X.2023.2261248","article-title":"Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies","volume":"12","author":"Gide","year":"2023","journal-title":"Oncoimmunology"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2343272","article-title":"The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced Malignancies","volume":"20","author":"Shapira-Frommer","year":"2024","journal-title":"Future Oncol"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(\u2606)","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0171","article-title":"Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade","volume":"2","author":"da Silva","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.09.017","article-title":"Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma","volume":"29","author":"Xu","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B275","doi-asserted-by":"publisher","first-page":"1942673","DOI":"10.1080\/2162402X.2021.1942673","article-title":"TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus\u2212related hepatocellular carcinoma","volume":"10","author":"Yu","year":"2021","journal-title":"Oncoimmunology"},{"key":"B276","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-019-1917-0","article-title":"TNF-alpha-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer","volume":"17","author":"Zheng","year":"2019","journal-title":"J Transl Med"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: A phase ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"Harding","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B279","doi-asserted-by":"publisher","first-page":"200773","DOI":"10.1016\/j.omton.2024.200773","article-title":"Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party","volume":"32","author":"Lu","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02172","article-title":"Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma","volume":"42","author":"Hamid","year":"2024","journal-title":"J Clin Oncol"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.02.006","article-title":"Exhausted CD8(+) T cells face a developmental fork in the road","volume":"44","author":"Zander","year":"2023","journal-title":"Trends Immunol"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.6.991","article-title":"Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques","volume":"189","author":"Jin","year":"1999","journal-title":"J Exp Med"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1126\/science.283.5403.857","article-title":"Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes","volume":"283","author":"Schmitz","year":"1999","journal-title":"Science"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1038\/nri3740","article-title":"T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion","volume":"14","author":"Speiser","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005147","article-title":"Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors","volume":"10","author":"Sanborn","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B290","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12032-023-01959-1","article-title":"CD27 agonism coordinates with CD28 and 4-1BB signal to augment the efficacy of CAR-T cells in colorectal tumor","volume":"40","author":"Zhang","year":"2023","journal-title":"Med Oncol"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0541","article-title":"Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity","volume":"9","author":"Li","year":"2019","journal-title":"Cancer Discovery"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0376-4","article-title":"Targeting CD39 in cancer","volume":"20","author":"Moesta","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000186","article-title":"On the mechanism of anti-CD39 immune checkpoint therapy","volume":"8","author":"Allard","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158068","article-title":"CD39 regulation and functions in T cells","volume":"22","author":"Timperi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B295","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40364-023-00500-w","article-title":"Review immune response of targeting CD39 in cancer","volume":"11","author":"Liu","year":"2023","journal-title":"biomark Res"},{"key":"B296","doi-asserted-by":"publisher","first-page":"113066","DOI":"10.1016\/j.biopha.2022.113066","article-title":"CD39 - A bright target for cancer immunotherapy","volume":"151","author":"Guo","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102288","article-title":"CD137 as an attractive T cell co-stimulatory target in the TNFRSF for immuno-oncology drug development","volume":"13","author":"Hashimoto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B298","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.canlet.2020.11.041","article-title":"CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma","volume":"499","author":"Muth","year":"2021","journal-title":"Cancer Lett"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010113","article-title":"First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid Malignancies","volume":"13","author":"Carneiro","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1552","article-title":"A first-in-human study of cinrebafusp alfa, a HER2\/4-1BB bispecific molecule, in patients with HER2-positive advanced solid Malignancies","volume":"31","author":"Piha-Paul","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2973","article-title":"First-in-human study of utomilumab, a 4-1BB\/CD137 agonist, in combination with rituximab in patients with follicular and other CD20(+) non-hodgkin lymphomas","volume":"26","author":"Gopal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002863","article-title":"First-in-human phase I\/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas","volume":"9","author":"Piha-Paul","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0420-8","article-title":"Rational design of anti-GITR-based combination immunotherapy","volume":"25","author":"Zappasodi","year":"2019","journal-title":"Nat Med"},{"key":"B304","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.178146","article-title":"Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages","volume":"10","author":"Sato","year":"2025","journal-title":"JCI Insight"},{"key":"B306","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-24-0103","article-title":"CSF1R inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: A phase I study of vimseltinib","volume":"30","author":"Gelderblom","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: A therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1277810","article-title":"Making \u201ccold\u201d tumors \u201chot\u201d- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report","volume":"14","author":"Tong","year":"2023","journal-title":"Front Immunol"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213222","article-title":"Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy","volume":"14","author":"Shi","year":"2023","journal-title":"Front Immunol"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1241208","article-title":"It\u2019s high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer","volume":"14","author":"Yao","year":"2023","journal-title":"Front Immunol"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-4425","article-title":"BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGFbeta signaling to durably suppress tumor growth","volume":"83","author":"Boreddy","year":"2023","journal-title":"Cancer Res"},{"key":"B312","doi-asserted-by":"publisher","DOI":"10.1111\/acem.2018.25.issue-7","article-title":"Immune-related adverse events in cancer patients","volume":"25","author":"Pallin","year":"2018","journal-title":"Acad Emerg Med"},{"key":"B313","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coi.2021.02.002","article-title":"Adverse events induced by immune checkpoint inhibitors","volume":"69","author":"Perdigoto","year":"2021","journal-title":"Curr Opin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1548234\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:30:12Z","timestamp":1743467412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1548234\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":313,"alternative-id":["10.3389\/fimmu.2025.1548234"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1548234","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"1548234"}}